Introduction
Tazofirst 4.5 inj.
Tazofirst 4.5 Injection is a combination antibiotic containing piperacillin and tazobactam, used to treat severe bacterial infections. It combines a broad-spectrum penicillin antibiotic with a beta-lactamase inhibitor to overcome bacterial resistance.
Uses
This injection targets serious infections such as lower respiratory tract infections (like pneumonia), urinary tract infections, skin and soft tissue infections, intra-abdominal infections (e.g., appendicitis, peritonitis), bloodstream infections (septicemia), and hospital-acquired infections.
Benefits
Piperacillin kills bacteria by disrupting their cell wall formation, while tazobactam protects it from destruction by bacterial enzymes, making the treatment effective against resistant strains. It provides rapid action in hospitalized patients with complicated infections, often improving outcomes when other antibiotics fail.
How It Works
The piperacillin component inhibits bacterial cell wall synthesis, leading to bacterial death, and tazobactam blocks beta-lactamase enzymes produced by resistant bacteria. This synergy ensures broader coverage against gram-positive, gram-negative, and anaerobic bacteria.
Dosage
Typically administered intravenously as 4.5 g (4 g piperacillin + 0.5 g tazobactam) every 6-8 hours, depending on infection severity, patient kidney function, and weight; duration is usually 7-14 days. Dosage must be adjusted for renal impairment and is determined by a doctor.
Precautions
Avoid if allergic to penicillins, cephalosporins, or carbapenems; monitor for diarrhea, bleeding issues (especially with warfarin), seizures, or low potassium. Use cautiously in pregnancy, breastfeeding, kidney/liver disease, or with drugs like methotrexate or aminoglycosides; stop if severe rash or bloody stools occur
